Biologics in Hypereosinophilic Syndrome and Eosinophilic Granulomatosis with Polyangiitis

IF 2.7 3区医学 Q2 ALLERGY

Immunology and Allergy Clinics of North America Pub Date : 2024-08-16 DOI:10.1016/j.iac.2024.07.003

引用次数: 0

生物制剂在嗜酸性粒细胞增多症和嗜酸性粒细胞增多性多发性炎症中的应用。

嗜酸性粒细胞增多综合征（HES）和嗜酸性粒细胞肉芽肿伴多血管炎（EGPA）是由血液和组织中的嗜酸性粒细胞增多以及异质性临床表现所定义的复杂疾病。一直以来，这两种疾病的主要治疗方法是全身使用糖皮质激素。然而，最近出现了直接或间接针对嗜酸性粒细胞的生物制剂，这为我们提供了新的途径，可在减少毒性的同时提高疗效。在本文中，我们总结了支持在 HES 和/或 EGPA 中使用特定生物制剂的证据，并提供了在患者中临床使用这些药物的框架。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Immunology and Allergy Clinics of North America 医学-过敏

CiteScore

5.40

自引率

3.80%

发文量

审稿时长

>12 weeks

期刊介绍： Immunology and Allergy Clinics of North America updates you on the latest trends in patient management; keeps you up to date on the newest advances; and provides a sound basis for choosing treatment options. Each issue focuses on a single topic in immunology and allergy and is presented under the direction of an experienced guest editor. Topics include allergens, immunotherapy, anaphylaxis, asthma, drug allergy, eosinophilrelated disorders, food allergy, immunodeficiency states (non-HIV), basic science, mast cell disorders, rhinitis and sinusitis, and urticaria and angioedema. Immunology and Allergy Clinics of North America is published four times each year, in February, May, August, and November.